Go Pro
NASDAQ:LIAN

LianBio (LIAN) Stock Price, News & Analysis

LianBio logo
$0.06 0.00 (0.00%)
As of 09/23/2026

About LianBio Stock (NASDAQ:LIAN)

Advanced

Key Stats

Today's Range
$0.04
$0.06
50-Day Range
$0.03
$0.11
52-Week Range
$0.27
$4.99
Volume
2,000 shs
Average Volume
1.04 million shs
Market Capitalization
$6.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

LianBio was a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines in China and other key Asian markets. The company’s business model centered on partnering with biotechnology and pharmaceutical companies to obtain regional rights to promising therapies and advance them through clinical development, regulatory review and potential commercialization.

LianBio’s activities historically spanned several therapeutic areas, including cardiovascular disease, oncology, immunology and other serious conditions with significant unmet medical needs. Its pipeline included internally and partner-developed programs, with development strategies tailored to patients and regulatory requirements in Greater China and selected Asia-Pacific markets.

Founded in 2019 with backing from Perceptive Advisors, LianBio was headquartered in Shanghai and operated as a cross-border drug-development platform. Dr. Carsten Brunn served as the company’s president and chief executive officer during its public-company period. LianBio later undertook a strategic restructuring and ceased operating as a publicly traded company, making its historical business and pipeline the primary context for the NASDAQ: LIAN listing.

AI Generated. May Contain Errors.

Receive LIAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LianBio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LIAN Stock News Headlines

MeiraGTx Holdings PLC
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about what $375,000 did five years ago, even though no statement shows the change. Central banks have bought over 1,000 tonnes of gold a year for three straight years, using the same published data now explained in a free guide. The guide breaks down what's driving the shift in plain English, so readers can see the numbers for themselves.tc pixel
LianBio to Wind Down Operations, Declares Special Dividend
LianBio Shares Gain After Co Announces Plans to Wind Down
See More Headlines

LIAN Stock Analysis - Frequently Asked Questions

LianBio's stock was trading at $0.0950 at the beginning of the year. Since then, LIAN shares have decreased by 37.4% and is now trading at $0.0595.

LianBio (NASDAQ:LIAN) released its earnings results on Monday, March, 27th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.10.

LianBio (LIAN) raised $325 million in an initial public offering on the week of November 1st 2021. The company issued 20,300,000 shares at a price of $16.00 per share. Goldman Sachs, Jefferies and BofA Securities acted as the underwriters for the IPO.

Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LianBio investors own include Arista Networks (ANET), NVIDIA (NVDA), ServiceNow (NOW), Broadcom (AVGO), Novo Nordisk A/S (NVO), PACCAR (PCAR) and Super Micro Computer (SMCI).

Company Calendar

Last Earnings
3/27/2023
Today
9/24/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:LIAN
CIK
1831283
Fax
N/A
Employees
110
Year Founded
2019

Profitability

EPS (Trailing Twelve Months)
($0.81)
Trailing P/E Ratio
N/A
Forward P/E Ratio
0.02
P/E Growth
N/A
Net Income
-$110.29 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-33.17%
Return on Assets
-30.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.06
Quick Ratio
10.06

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.71 per share
Price / Book
0.02

Miscellaneous

Outstanding Shares
108,063,000
Free Float
99,861,000
Market Cap
$6.43 million
Optionable
Not Optionable
Beta
0.23

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:LIAN) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners